at Zacks.com (Jan 15, 2015)
Sarepta Therapeutics (SRPT +8%) moves up on the back of on a positive article in Seeking Alpha today, saying the stock looks "ridiculously overvalued" at current levels. Contributor Sean Anderson notes a number of potential catalysts to move the stock higher, but most significant is how little attention the stock currently gets on the Street, which could quickly change if of it's eteplirsen, a potential blockbuster treatment for Duchenne's disease, to receive early approval.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Benzinga.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at Zacks.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs